TY - JOUR
T1 - Soluble CD163
T2 - a biomarker linking macrophages and insulin resistance
AU - Parkner, Tina
AU - Sørensen, L P
AU - Nielsen, A R
AU - Fischer, C P
AU - Bibby, Bo Martin
AU - Nielsen, S
AU - Pedersen, B K
AU - Møller, H J
PY - 2012/6
Y1 - 2012/6
N2 - Aims/hypothesis Soluble CD163 (sCD163) was recently identified as a strong risk marker for developing type 2 diabetes. We hypothesised that sCD163 independently associates with insulin resistance. Methods This cross-sectional study includes 234 participants: 96 with type 2 diabetes, 34 with impaired glucose tolerance (IGT) and 104 with normal glucose tolerance (NGT), matched for sex and BMI. Glucose-lowering medication was paused for 1 week before plasma samples were obtained for determination of sCD163 and other inflammatory and metabolic variables. Insulin resistance was estimated by homeostasis model assessment of insulin resistance (HOMA-IR). Results Concentrations of sCD163 were 1.95 mg/l (0.63-6.97) in individuals with type 2 diabetes, 1.64 mg/l (0.58-4.19) in those with IGT, and 1.48 mg/l (0.48-4.11) (median [range]) in those with NGT (p<0.0001). In univariate analyses, sCD163 correlated significantly with HOMA-IR (R00.44), insulin (R00.41), glucose (R00.30), triacylglycerol (R00.29) and HDL-cholesterol (R0-0.34) (all p<0.0001). All but glucose remained significant when adjusting for age, sex, BMI and glycaemic group. In univariate regression analyses, HOMA-IR was associated with sCD163, C-reactive protein (CRP), TNF-a and IL-6 (all p=0.0001). An increase of 50% in sCD163 resulted in an estimated increase in HOMA-IR of 36% (95% CI 26, 48; p<0.0001). In multiple linear regression analyses, sCD163 (p=0.001) and CRP (p00.01) remained independent predictors of HOMA-IR, whereas TNF-a and IL-6 did not. Conclusions/interpretation Macrophage-specific sCD163 was strongly associated with insulin resistance independently of TNF-a and other predictors. Moreover, sCD163 was associated with well-known variables of the metabolic syndrome.
AB - Aims/hypothesis Soluble CD163 (sCD163) was recently identified as a strong risk marker for developing type 2 diabetes. We hypothesised that sCD163 independently associates with insulin resistance. Methods This cross-sectional study includes 234 participants: 96 with type 2 diabetes, 34 with impaired glucose tolerance (IGT) and 104 with normal glucose tolerance (NGT), matched for sex and BMI. Glucose-lowering medication was paused for 1 week before plasma samples were obtained for determination of sCD163 and other inflammatory and metabolic variables. Insulin resistance was estimated by homeostasis model assessment of insulin resistance (HOMA-IR). Results Concentrations of sCD163 were 1.95 mg/l (0.63-6.97) in individuals with type 2 diabetes, 1.64 mg/l (0.58-4.19) in those with IGT, and 1.48 mg/l (0.48-4.11) (median [range]) in those with NGT (p<0.0001). In univariate analyses, sCD163 correlated significantly with HOMA-IR (R00.44), insulin (R00.41), glucose (R00.30), triacylglycerol (R00.29) and HDL-cholesterol (R0-0.34) (all p<0.0001). All but glucose remained significant when adjusting for age, sex, BMI and glycaemic group. In univariate regression analyses, HOMA-IR was associated with sCD163, C-reactive protein (CRP), TNF-a and IL-6 (all p=0.0001). An increase of 50% in sCD163 resulted in an estimated increase in HOMA-IR of 36% (95% CI 26, 48; p<0.0001). In multiple linear regression analyses, sCD163 (p=0.001) and CRP (p00.01) remained independent predictors of HOMA-IR, whereas TNF-a and IL-6 did not. Conclusions/interpretation Macrophage-specific sCD163 was strongly associated with insulin resistance independently of TNF-a and other predictors. Moreover, sCD163 was associated with well-known variables of the metabolic syndrome.
U2 - 10.1007/s00125-012-2533-1
DO - 10.1007/s00125-012-2533-1
M3 - Journal article
C2 - 22450890
SN - 0012-186X
VL - 55
SP - 1856
EP - 1862
JO - Diabetologia
JF - Diabetologia
IS - 6
ER -
